InnoCare Secures Approval for Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
InnoCare Pharma has received approval to commence a Phase II clinical trial for its TYK2 inhibitor, ICP-488, aimed at treating Sjögren's Syndrome. This development marks a significant step forward in addressing this autoimmune condition in the Chinese market.